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Metabolic disorderWe have carried out an extensive in silico analysis on 18 disease associated missense mutations found in
electron transfer ﬂavoprotein (ETF), and found that mutations fall essentially in two groups, one in which
mutations affect protein folding and assembly, and another one in which mutations impair catalytic activity
and disrupt interactions with partner dehydrogenases. We have further experimentally analyzed three of
these mutations, ETFβ-p.Cys42Arg, ETFβ-p.Asp128Asn and ETFβ–p.Arg191Cys, which have been found in
homozygous form in patients and which typify different scenarios in respect to the clinical phenotypes. The
ETFβ-p.Cys42Arg mutation, related to a severe form of multiple acyl-CoA dehydrogenase deﬁciency (MADD),
affects directly the AMP binding site and intersubunit contacts and impairs correct protein folding. The two
other variations, ETFβ-p.Asp128Asn and ETFβ–p.Arg191Cys, are both associated with mild MADD, but these
mutations have a different impact on ETF. Although none affects the overall α/β fold topology as shown by
far-UV CD, analysis of the puriﬁed proteins shows that both have substantially decreased enzymatic activity
and conformational stability. Altogether, this study combines in silico analysis of mutations with
experimental data and has allowed establishing structural hotspots within the ETF fold that are useful to
provide a rationale for the prediction of effects of mutations in ETF.ase deﬁciency; WT, wild type;
k; CD, circular dichroism; SPR,
temperature; Cm, denaturant
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Mutations in the ETFA/ETFB or ETFDH genes, which encode the two
subunits of Electron Transfer Flavoprotein (ETF) and ETF-ubiquinone
oxidoreductase (ETF-QO), respectively, cause multiple acyl-CoA dehy-
drogenase deﬁciency (MADD), a congenital metabolic disease with a
broad clinical expression [1]. The systematic application of newborn
screening programs has allowed for a wider coverage of MADD
genotypes, that range from missense or nonsense mutations to
frameshift. One of the proteins affected in this disorder is ETF, a key
enzyme in the mitochondrial fatty acid beta oxidation and amino acid
degradation pathways, which transfers electrons from at least 12
dehydrogenases via ETF-QO to the respiratory chain. As in many other
metabolic disorders, clear genotype-phenotype relationships remain
elusive in MADD: in particular for milder disease forms, it is expected
that the mutant proteins are partially functional and that cellular and
environmental factors such as temperature and cofactors can modulatedisease expression [2]. Progress in this issue has however also been
constrained by the fact that only a very limited number ofmutations has
been characterised upon recombinant expression of the variant
proteins. However, substantial steps forward can be achieved if the
available data on clinical mutations are merged with a structural and
functional analysis of the protein affected. In this paper we have
investigated for mutational hotspots on the ETF structure, by analysing
the protein for particularly susceptible regions in which MADD-related
ETF variations detected in patients map. Complementary experimental
validation for the putative mutational hotspots identiﬁed was subse-
quently obtained by carrying out a biochemical and biophysical analysis
of puriﬁed ETF variants with representative disease-causing mutations.
The data gathered by this strategy contribute to a better understanding
of themolecular factorsunderlying functionaldeﬁciency andmay, in the
long term, provide a framework for the design of novel therapies.2. Materials and methods
2.1. Chemicals
All reagentswere of the highest purity grade commercially available.
Octanoyl-CoA, FAD, AMP and urea were purchased from Sigma.
Isopropyl-β-D-thiogalactopyranoside (IPTG) was purchased from
VWR International.
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The crystallographic structures of human ETF (PDB code: 1efv, [3])
and ETF:MCAD complex (PDB code: 1T9G, [4]) were inspected using
PyMOL (DeLano Scientiﬁc). Analysis of the molecular interactions,
cofactor contacts, topological features and generation of models for
the variants was carried out using the WhatIF web server [5] and the
PDBsum database [6]. The PolyPhen (Polymorphism Phenotyping)
web server was used to predict the effect of amino acid variations on
protein structure and function [7]. The input for this server was the
UniProt accession number (ETFα: P13804 and ETFβ:P38117), se-
quence position and the two amino acid variants characterizing the
desired mutation.2.3. ETF expression in E. coli JM109 cells
The pK-lac-ETF-αβ3(C/T) plasmid encoding both ETF subunits (here
named pWt), described previously [8], was used as DNA template in the
production of the two novel mutants, the ETFβ−p.Cys42Arg and
ETFβ−p.Arg191Cys. The mutants were generated using the Quick
change mutagenesis kit (Stratagene) as recommended by the manu-
facturer. Mutagenic primers were 5’-CCATGAACCCCTTCCGTGA-
GATCGCGGTGG-3’ for the ETFβ−p.Cys42Arg variant, and 5’-
GAGGCTCAACGAGCCCTGCTACGCCACGCTG-3’ for the ETFβ−p.
Arg191Cys mutant (altered bases are underline and in bold type). The
second mutagenic primers required were the reverse complements of
those shown. After PCR screening the sections containing the mutation
were sequenced to exclude PCR errors and subcloned back into the
original plasmid. The ETFβ−D128Nmutant, also used in these studies,
was already available [9]. E. coli JM109 cells transformed with the
respective plasmid, pWt, pC42R, pD128N, pR191C, were grown in LB
(Luria–Bertani) supplemented with 10 μgml-1 kanamycin at 30 °C or
37 °C in a shaking incubator until OD532 of 0.5-0.8was reached. The cells
were then inducedwith 1 mM IPTG for 4 hours. Cells were harvested by
centrifugation, re-suspended in 10 mMHepes, 10% ethylene glycol and
0.5 mM phenylmethylsulphonylﬂuoride (Roth) in presence of DNase
(Applichem) and disrupted in a French press. The soluble extract was
obtained by centrifugation at 12,000 g for 30 minutes and used for the
ETF activity assays [10] and for SDS-PAGE followed by western blotting
analyses according to [11]. An ETF polyclonal antibody raised in rabbits
against puriﬁed recombinant wild type ETF proteinwas used to identify
ETF proteins and visualized with peroxidase conjugated secondary
antibody reaction with 1-step TMB-Blotting (Pierce).2.4. Co-expression of Molecular chaperones with ETFβ−p.Cys42Arg
Different conditions were used to improve ETFβ−p.Cys42Arg
mutant expression, always using LB as growth medium. First, E. coli
cells transformed with pC42R plasmid were grown at 30 °C and 18 °C.
Induction was made with 1 mM IPTG. JM109 E. coli cells were co-
transformed with the pC42R plasmid and a molecular chaperone
plasmid, pOFX-BADSL2 and pOFX-BADKJE2, respectively for the
GroES/EL complex and DnaK,J and GrpE [12]. Cells transformed
with the ETFβ−p.Cys42Arg and with pOFX-BAD2 empty plasmid,
control vector, or with the plasmid encoding the respective molecular
chaperone system, were grown in LB supplemented with 10 μgml-1
kanamycin and 10 μgml-1 tetracycline at 30 °C and 18 °C until OD532 of
0.5-0.8 was reached. Cells were then induced with 0.2% arabinose and
30 minutes later with 1 mM IPTG. Samples were withdrawn at 1, 3, 6
and 20 hours after induction with IPTG. Cells were harvested by
centrifugation and treated with Bug Buster solution (Novagen),
soluble and insoluble fractions were analysed by SDS-PAGE and
western blot analysis. Soluble fractions were also used in ETF activity
assays [10].2.5. Protein Puriﬁcation and biochemical assays
Soluble extract from 3 L culture growth of wild type, and ETFβ−p.
Asp128Asn and ETFβ−p.Arg191Cys mutants, was applied on a Q-
Sepharose fast ﬂow column (GE Healthcare, 20 ml) previously
equilibrated in 10 mM Hepes, 10% ethylene glycol and 0.5 mM
phenylmethylsulphonylﬂuoride (buffer A). The column was washed
with 5 volumes buffer A, and bound proteins were eluted by a linear
gradient of 0 - 1 M NaCl in buffer A. Pure ETF eluted at a salt
concentration around 250 mM, and purity was conﬁrmed by SDS/
PAGE. Protein concentration was determined using the Bradford
assay. Flavin content was determined using the molar extinction
coefﬁcient ε436nm=13400 M-1.cm-1 reported for FAD bound to ETF
[13]. ETF enzyme activity was measured following 2,6-dichlorophe-
nolindophenol (DCPIP) reduction at 600 nm in a coupled assay in
which recombinant human MCAD and octanoyl-CoA were employed,
as described in [10]. One unit of catalytic activity is deﬁned as nmol of
DCPIP reduced per minute, in the conditions used in the assay. All
speciﬁc activities reported are based on total ﬂavin content. Pure ETF
fractions with a 2.5 fold molar excess FAD were fast-frozen using
liquid nitrogen and stored at -80 °C.
2.6. Spectroscopic methods
Before each experiment FAD excess added to buffers as a
preservative was removed by extensive washing using ultra ﬁltra-
tion/dilution, and all experiments were performedwith pure proteins
containing full occupancy of FAD site. UV/visible spectra were
recorded at room temperature in a Shimadzu UVPC-1601 spectrom-
eter with cell stirring. Fluorescence spectroscopy was performed
using a Cary Eclipse instrument. For tryptophan emission excitation
wavelength was set at 280 nm, and FAD emission was followed
setting excitation wavelength at 436 nm; slits were 5 and 10 nm for
excitation and emission, respectively. Typically protein concentration
was 1 μM. CD spectra were recorded on a Jasco J-815 spectro-
polarimeter with a cell holder thermostatically controlled with a
Peltier. A quartz polarized 1 mm path length quartz cuvette (Hellma)
was used, and protein concentrations were typically 0.1 mg.ml-1.
2.7. Surface Plasmon Resonance
Surface plasmon resonance (SPR) experiments were performed on a
BIAcore™ 2000 Instrument using NTA sensor chip (BIAcore, Inc.). The
NTA sensor chip is designed to bind histidine tagged molecules after
nickel activation of the surface. The surface was prepared as recom-
mended by the manufacturer. The running buffer consisted of 10 mM
Hepes, pH 7.4, 10% ethylene glycol, 50 mM NaCl, 0.005% Tween 20.
Recombinant humanMCADwith a histidine tagwas immobilized in ﬂow
cell 2. The dehydrogenase was captured by manually injecting 25 μl of a
200nMsolutionat aﬂowrateof 5 μl min-1. Flowcell 1wasused to correct
for refractive index changes and nonspeciﬁc binding. ETF (ETF-WT,
ETFβ−p.Asp128Asn or ETFβ−p.Arg191Cys) in 50 nM solutions was
injected over ﬂow cells 1 and 2 at a ﬂow rate of 40 μl min-1, during 90
seconds. All SPR experiments were done at 25 °C.
2.8. Thermal stability
Thermal unfolding with a linear temperature increase was
followed using circular dichroism (ellipticity variation at 222 nm)
and ﬂuorescence spectroscopy, tryptophan emission (λex=280 nm;
λem=340 nm), FAD emission (λex=436 nm; λem=530 nm) and
FRET from tryptophan emission to FAD cofactor (λex=280 nm;
λem=530 nm). In all experiments, a heating rate of 1 °C min-1 was
used, and temperature was increased from 30 to 90 °C. Data were
analysed according to a two-state model, and ﬁts to the transition
curves were made using OriginPro8.
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The denaturation curves were measured diluting ETF (ETF-WT,
ETFβ−p.Asp128Asn or ETFβ−p.Arg191Cys) in different urea con-
centrations and the tryptophan emission spectrumwas recorded after
15 minutes of incubation at 25 °C. Transition curves were determined
plotting the average emission wavelength against urea concentra-
tions. Data were analysed according to a two-state model, and ﬁts to
the transition curves were made using OriginPro8.
3. Results and discussion
3.1. Mutational hotspots in the ETF structure
A number of genetic defects in the ETFA/ETFB gene account for
MADD. Most of the variations detected in patients are of the missense
type, although frameshift and nonsense mutations are also described
[14]. As the effect of modifying a single amino acid in ETF can be rather
broad with respect to clinical expression, the possibility to predict
whether a point mutation in a particular region of the protein would
affect the folding, stability or activity, would be a potentially very useful
parameter to establish genotype-phenotype relationships. In order to
ﬁll this gap we have set to deﬁne a structural mapping of mutations in
ETF. For this purposeour strategywas twofold. First,wehave compiled a
list of known disease-associated missense mutations described for
human ETF,whose predicted effectswere analysed using a combination
of in silico tools for mutagenesis predictions and structural analysis
(Table 1). Secondly, we have analysed the ETF crystal structure in
respect to speciﬁc structural factors that, if affected by mutations, are
expected to perturb the structural integrity or the biological activity of
the protein [3,4]. In this respect, we have analysed: i. positions that
correspond to AMP-protein interactions; ii. residues that are involved in
H-bond connections at the ETFα/ETFβ contact surface; iii. highly
conserved segments throughout ETF orthologues; iv. amino acids
involved in FAD binding or in the stabilization of the FAD moiety, and;
v. positions involved in interactions with medium-chain acyl-CoA
dehydrogenase (MCAD), both the anchor loop and the FAD domain. At
this stage positions involved in the interaction with ETF-QO were not
possible to analyze once there is no structural information available on
the ETF:ETF-QO complex.
Merging the data obtained by these two complementary approaches
shows that particular regions of the ETF structure are more susceptibleTable 1
Mutations in ETF related to MADD.
PSIC score Structural rationale
ETF α
p.Leu95Val 0.085 Near inter subunit H-bonded region
p.Gly116Arg 2.667 Changes at buried site: hydrophobic
p.Arg122Lys 1.507 Change at buried site hydrophobicit
p.Phe144Ser 1.781 Changes at buried site: hydrophobic
p.Val157Gly 2.346 Closest contact is ETFβ-Ser223. Cavi
p.Val165Ala 1.373 Near inter subunit H-bonded region
p.Leu212Pro 2.798 Change at buried site hydrophobicit
p.Arg249Cys 3.472 Disruption of FAD binding site. Stab
p.Gly255Val 2.988 Maps at FAD interacting region.
p.Thr266Met 2.834 Disruption of FAD binding site. Hyd
p.Gly267Arg 2.982 Maps at FAD interacting region. Cha
ETF β
p.Ala17Pro 1.612 Maps at FAD and AMP interacting re
p.Cys42Arg 3.343 Disruption of AMP binding site. Cha
p.Asp128Asn 2.438 Charge change at buried site. Maps
p.Arg164Gln 2.492 Charge change at buried site. Near i
p.Arg191Cys 3.515 Removal of charged residue. Contac
The PSIC score is the position-speciﬁc independent count parameter computed by PolyPheto deleterious modiﬁcations than others, and the clustering of the
known mutations in those structure segments is rather suggestive of
structural hotspots for MADD mutations (Fig 1 and Fig. S1). This is
clearly noted on ETFα, in which mutations map essentially in two
regions: one corresponding to the region involved essentially in
interactions with the ETFβ subunit (Glu91-Val165), and the other a
conserved region rich in FAD and MCAD interacting residues and inter-
subunit interactions (Ala244-Thr295). Clearly mutations in the ﬁrst
region may result in folding defects due to poor dimer assembly or
protein destabilisation, as changes in these positions modify the
chemistry of buried sites and may result in cavity creation. The latter
may arise if an amino acid with a bulkier side chain is replaced by
another with a smaller volume (e.g. ETFα-p.Val157Gly) or if a charged
residue replaces an hydrophobic one (e.g. ETFα-p.Gly116Arg) (Table 1).
On theother hand,mutations in the second regionhave an impact on
catalysis. This occurs either by disturbing directly the FAD protein
interactions, or the second coordination sphere ligands, which are
importantmodulators of the redox properties of the cofactor. In fact, the
chemical and catalytic properties of the ﬂavin are tightly controlled by
the polypeptide, not only at the level of the residues involved in direct
close-range interactions (i.e. within the ﬁrst coordination sphere), but
also by those which are further away from the organic cofactor but that
are nevertheless connected to it through hydrogen-bond networks or
other weak interactions (i.e. second coordination sphere). Also, this
segment comprises positions of the FAD domain that are known to be
involved in complex formationwithMCAD [15]. Therefore,mutations in
this region are expected to affect mostly the biological activity of the
protein, although concurrent destabilization may also occur.
In respect to the ETFβ subunit, the scenario is not so clear as a
result of the fact that only 5 missense mutations are known in this
subunit. Nevertheless, some highly susceptible regions can be
deﬁned: those involving two N-terminal segments of ETFβ which
harbour simultaneously FAD and AMP binding residues (ETFβ Arg5-
Ile20 and ETFβ Val34-Ala45), a region rich in AMP-protein interac-
tions (ETFβ Gly123-Thr134), and segments involved in interactions
with partner proteins, namely the recognition peptide within the
anchor domain that constitutes the primary interaction site of partner
proteins with ETF (ETFβ Asp184-Lys200) [4], and also a short segment
centred around ETFβ−Glu165, an essential residue that destabilises
positions compatible with fast inter-protein electron transfer, thus
ensuring high complex dissociation rates [15], a strict requirement for
subsequent interaction of reduced ETF with ETF:QO.Ref
. [29]
ity, overpacking and charge. [23,30]
y. Closest contact is ETFβ-Gln146. Affects subunits interface. [20]
ity and cavity creation. [20]
ty creation. Increase in ﬂexibility. Affects subunits interface. [31]
. [20]
y. [20]
ilizes FAD semiquinone. Contacts with MCAD. [20].
[32]
rophobicity change at buried site. Contacts with MCAD. [9,23,30]
rged residue inserted in turn. Contacts with MCAD. [32]
gions. Maps nearby ETFα-Ile284. [33]
nges at buried site: overpacking, hydrophobicity and charge. [19,20]
at AMP interacting regions. Maps nearby ETFα-Tyr149. [9,16]
nter subunit H-bonded region. Maps nearby ETFα-Asn118. [34]
ts with MCAD. [20]
n[7].
Fig. 1. Structural features mapped on ETF sequence. Analysis of the ETF structure (PDB:
1efv) allowed the identiﬁcation of the regions involved in FAD and AMP binding, MCAD
interactions, andH-bondingbetween the ETFα andETFβ subunits,which are represented as
boxed segments in respect to the primary sequence positions. Stars denote MADD
mutations [14] and are ﬁlled according to the clinical phenotype: severe forms (ﬁlled stars)
and mild (open stars).
1073B.J. Henriques et al. / Biochimica et Biophysica Acta 1802 (2010) 1070–10773.2. Analysis of prototypic mutations
In order to provide complementary experimental validation of the
putative mutational hotspots identiﬁed in ETF, three mutations in
ETFβ were selected for subsequent analysis: ETFβ−p.Cys42Arg,
ETFβ−p.Asp128Asn and ETFβ−p.Arg191Cys. With the exception of
ETFβ−p.Asp128Asn [9,16], none of these mutations had been
previously expressed and puriﬁed for a thorough in vitro functional
and structural characterisation. All three mutations were detected in
patients homozygous for the respective mutations allowing to relate
the results to the phenotypes. Also, this selection ﬁlls a gap in respect
to the characterisation of mutations in the ETFβ subunit, in which a
lower number of MADD related mutations have been described
compared to ETFα. Although an all-embracing division cannot be
established, these mutations typify different functional and folding
effects. To better predict the structural effect of these individual
mutations we have built molecular models of these variants by
homologymodellingwith respect to thewild type protein (Fig. 2). The
ETFβ−p.Cys42Arg mutation, associated to a severe clinical expres-
sion, is expected to severely affect the interaction with the AMP
cofactor, which plays a key role in the assembly of the ETF dimerFig. 2. Structural details around the mutated positions.The cartoons represent magniﬁcation
the mutated and the original residues, as well nearby important. Straight dotted lines repre[17,18]. The ETFβ−p.Asp128Asn modiﬁcation, which occurs at an
outer layer of the FAD interacting moieties, has been shown to affect
the plasticity of the tertiary structure and decrease directly the
speciﬁc activity [16], and its mutation likely affects a stabilizing H-
bond to ETFβ−Lys11 (Fig. 2). Finally, the ETFβ−p.Arg191Cys
mutation is hypothesised to affect catalysis by impairing interaction
with the partner dehydrogenase, as this residue is localized in the
anchor domain. Also, analysis of the model of the mutant variation
shows that removal of ETFβ−Arg191 may destabilize the fold by
disrupting electrostatic interactions with the nearby ETFβ−Glu47,
ETFβ−Arg51 and ETFβ−Glu54 (Fig. 2). The patients with the latter
two mutations display mild forms of the disease, indicating that the
modiﬁed conformation is nevertheless able to fold and assemble as a
dimer, retaining some catalytic proﬁciency.
3.3. Mutations affect folding efﬁciency
The effect of eachmutation on the efﬁciency of protein folding was
investigated by heterologous expression of the different variants and
differential analysis of the soluble versus insoluble protein produced,
in respect to that of wild type ETF and comparing cell cultures with
standardized induction protocols displaying superimposable cell
growth characteristics. Therefore, any difference strictly results from
distinct expression levels of the heterologously expressed protein.
Since it has been previously demonstrated that expression of ETFβ-p.
Asp128Asn was improved upon cell growth at 30 °C [9], over
expression all of the analysed ETF variants was carried out both at
30 and 37 °C (Fig. 3). The results obtained show that while wild type
ETF and the mild mutant variants (ETFβ−p.Asp128Asn and ETFβ−p.
Arg191Cys) were well expressed as soluble proteins, the severe
phenotype mutation (ETFβ−p.Cys42Arg) was not (Fig. 3). The
expression level of ETFβ−p.Arg191Cys was 87% of that of the soluble
protein detected in the wild type whereas that of ETFβ−p.Asp128Asn
was decreased to 48%. This suggests that while the expression of the
variant ETFβ−p.Arg191Cys is almost unaffected, the ETFβ−p.
Asp128Asn modiﬁcation has a destabilizing effect on the folding
process, making it rather susceptible to misfold and aggregate, or be
degraded. This observation during cell expression agrees with the
data obtained in vitro using puriﬁed ETFβ−p.Asp128Asn for which a
higher proteolytic susceptibility was determined [16].
On the other hand, expression of the ETFβ−p.Cys42Arg variant
yielded only 10% of ETF protein in the soluble fraction, indicating that
this mutation affecting the AMP binding severely impairs ETF folding
and assembly. Further expression assays lowering the E. coli growth
temperature to 18 °C in an attempt to further improve conditions for
in cell folding did not change the scenario, and even at this low
temperature almost all the ETFβ−p.Cys42Arg protein expressed wents of the ETF structural regions in which the MADD variations are identiﬁed, overlaying
sent hydrogen bonds. Structures prepared using PyMOL.
Fig. 3. Expression levels of ETF variants at 30 and 37 °C.Expression of ETF variants at 30 and 37 °C was quantiﬁed from Western Blot analysis (left) and expressed in a bar graph
(right) in respect to that of the wild type protein. See text and materials and methods for details.
Fig. 4. Effect of molecular chaperones on the expression of soluble ETFβ-p.Cys42Arg.The
amount of the ETFβ-p.Cys42Arg variant expressed in the soluble (s) and insoluble (i)
form was quantiﬁed from western blots of cell extracts after inducing for 1 and 6 h the
co-expression of the molecular chaperones GroEL/ES (left) or DnaK/J/GprE (right). The
bar graph shows the relative fraction of soluble (light grey) and insoluble (dark grey)
protein. See text and materials and methods for details.
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blot analysis of skin ﬁbroblasts from a patient carrying this mutation
that showed no detectable ETF protein [19,20].
3.4. Molecular chaperones partly rescue ETFβ−p.Cys42Arg folding
An approach for the rescue of folding defects resulting from disease-
causing mutations is that of stimulating the so called proteostasis
network [21]. This involves recruiting the protein quality control
machinery and/or the action of small molecule substrates and cofactors
as effectors of the folding process. In order to investigate if molecular
chaperones could rescue the defective folding resulting from the
ETFβ−p.Cys42Arg mutation, we have carried out co-expression
experiments with the chaperonins GroEL and GroES (homologs of the
human mitochondrial Hsp60 and Hsp10 chaperone system), and the
chaperone DnaK (homolog of mammalian Hsp70s) and its cofactors
DnaJ and GrpE. This strategy has been shown to result in the effective
rescue of proteins with folding defects in other cases [22–25]. The
results obtained (Fig. 4) show that the molecular chaperones could in
fact partially rescue the protein to the soluble fraction. However,
enzymatic activity assays on the soluble fractions showed no detectable
ETF activity, indicating that althoughmolecular chaperones successfully
rescue some soluble conformations these are still be incorrectly folded
and/or with defective cofactor insertion: presumably these soluble
forms are still substantially destabilised and poor incorporation of FAD
and/or deﬁcient interaction with the partner dehydrogenases impair
activity.
3.5. Structure and conformational properties of the ETFβ−p.Asp128Asn
and ETFβ−p.Arg191Cys variant proteins
The ETFβ−p.Arg191Cys variant was puriﬁed to homogeneity and
spectroscopically characterised. The ETFβ−p.Asp128Asn was also
puriﬁed and characterized as described in [16] and the spectroscopic
data fromthis variantwere redrawn frompublisheddata [16] inorder to
allow a direct comparison with the new variant described. The protein
fold and secondary structure were analysed using far-UV circular
dichroism (Fig. 5). The spectra obtained are typical of folded proteins
with a α/β fold, and with the clear α-helix ﬁngerprint with minima at
208 and222 nm. Themutant variantshave superimposable spectrawith
respect to that of wild type ETF, indicating that the mutations do not
disrupt the protein fold nor the secondary structure. Trp-emission
spectra, which are indicative of tertiary structure interactions, were also
recorded. ETF contains two Trp residues, and the ﬂuorescence emissionproperties of this amino acid ranges typically from 315 to 350 nm and
are related to solvent accessibility: amore solvent exposed Trpwill emit
at higher wavelengths. The results obtained show that both mutants
have 10 nm red-shifted maxima of the emitting band, with maximum
emission at 330 nm versus 320 nm of the wild type ETF (Fig. S2). This
suggests that the structure of the mutant variants is not as constrained
as that of the wild type ETF and that they display a more dynamic
tertiary structure. The spectroscopic ﬁngerprint of the catalytic FAD
cofactor was also analysed using visible absorption spectroscopy, which
is very sensitive to changes in the H-bound interaction network around
the cofactor. From the results obtained we could conclude that the
environment of the functional cofactor does not change signiﬁcantly in
any of the mutants, as the two characteristic absorption bands with
typical emission maxima at around 376 nm and 436 nm, are retained.
Overall, these results indicate that the ETFβ−p.Asp128AsnandETFβ−p.
Arg191Cys variants retain the fold and FAD interactions identical to
those of the wild type protein but the differences in Trp ﬂuorescence
properties suggest decreased compactness and structural constraints in
comparison to the wild type [16]. The latter aspect may have an impact
Fig. 5. Spectroscopic analysis (A) far-UV CD (B) Visible absorption. The different variants
were analysed in respect to their far-UV CD (A) and visible absorption (B) spectra (the
legend is common for both panels): a. ETFβ-p.Asp128Asn, b. ETFβ–WT, c. ETFβ–p.
Arg191Cys. Spectra were slightly offset for clarity of comparison. The data for the ETFβ-p.
Asp128Asn variantwas redrawn from [16]. See text andmaterials andmethods for details.
Fig. 6. Stability proﬁles of ETFβ-p.Asp128Asn and ETFβ–p.Arg191Cys variants. The
thermal (A) and chemical (B) denaturation proﬁles of the ETFβ-p.Asp128Asn (inverted
triangles) and ETFβ–p.Arg191Cys (open circles) were compared in respect to that of
wild type ETF (closed squares). The solid curves represent two-state sigmoid curves
from which the apparent midpoint denaturations were determined: melting tempera-
tures (Tm) of 52, 57 and 60 °C and midpoint denaturant concentrations (Cm) of 2.2, 2.9
and 3.9 M urea for ETFβ−p.Asp128Asn, ETFβ−p.Arg191Cys, and ETF-WT, respectively.
See text and materials and methods for details.
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efﬁcient interaction with the partner acyl-CoA dehydrogenases and to
an increased protein instability.
3.6. Protein instability andMCAD interactions underpin functional deﬁciency
The speciﬁc activity of the ETFβ−p.Asp128Asn and ETFβ−p.
Arg191Cys variants was only 30% of that of the wild type protein
(400 U/mg vs. 1300 U/mg), which shows that, in addition to the lower
folding efﬁciency, these mutant variants also display a decreased
speciﬁc activity [16]. Since the mutant proteins retain structural
features identical to those of the wild type protein under physiological
conditions, we have investigated if differences in stability and
interaction with the partner dehydrogenases could play a role. The
interaction between the ETF variants and the medium chain acyl-CoA
dehydrogenase (MCAD) was investigated in preliminary experiments
by surface plasmon resonance, using MCAD immobilized in a NTA-
sensor chip. The results obtained showed that the ETFβ−p.Asp128Asn
and ETFβ−p.Arg191Cys variants interact withMCAD, as an increase in
the resonance signal is observed; however, the magnitude of the
interaction at equilibrium was only 20-30% of that observed for wild
type ETF, which is suggestive of a weaker interaction (Fig. S3).
The effect of theβ−p.Asp128Asn and ETFβ−p.Arg191Cysmutations
on the conformational stability was also investigated spectroscopically
using far-UV CD and ﬂuorescence. Thermal denaturation of the proteins
was monitored by following secondary and tertiary structure from far-
UV CD and tryptophan and FAD ﬂuorescence emissions (Fig. 6). All thetechniquesusedyielded similar transition curves for eachof theproteins
analysed, showing that all methods are monitoring the same unfolding
event with no noticeable intermediates formed. The analysis showed
the same order of relative stabilities of the proteins involved: ETF-
WTNETFβ−p.Arg191CysNETFβ−p.Asp128Asn. The thermal stability
studies showed that wild type ETF unfolds at an apparent midpoint
unfolding temperature (Tm) of 60 °C, and that ETFβ−p.Arg191Cys is just
slightly destabilised (ΔTm=-3 °C, Tm=57 °C), whereas ETFβ−p.
Asp128Asn exhibits a more signiﬁcant destabilization (ΔTm=-8 °C,
Tm=52 °C). Chemical denaturation was followed using tryptophan
emission, and the curves allowed the determination of apparent
midpoint urea concentrations (Cm). The obtained values were 2.2, 2.9
and 3.9 M for ETFβ−p.Asp128Asn, ETFβ−p.Arg191Cys, and ETF-WT,
respectively (Fig. 6B). Again, the order of stabilities was the same as in
thermal denaturations indicating that the ETFβ−p.Asp128Asn variation
has a strongerdestabilizing effect than ETFβ−p.Arg191Cys. In fact itwas
already described that ETFβ−p.Asp128Asn exhibits some plasticity in
tertiary structure and decreased speciﬁc activity as a function of time
during incubation at 39 °C, in an in vitro mimic of a fever episode [16].
These differences among the studied variants can be rationalised from
the molecular models made for the ETFβ−p.Asp128Asn and ETFβ−p.
Arg191Cys variants (Fig. 2). The replacement of ETFβ−Asp128
propagates to the AMP coordination sphere by affecting an hydrogen
bond between Asp128 and Lys11, therefore substantially destabilising
the protein fold, as shown by thermal and chemical unfolding studies
(Fig. 6). Likewise, the ETFβ−p.Arg191Cys variation also impacts on the
conformational stability of the fold as removal of ETFβ−Arg191
1076 B.J. Henriques et al. / Biochimica et Biophysica Acta 1802 (2010) 1070–1077disrupts salt bridges with Glu47 and Glu57 at the nearby α1 helix. This
case illustrates how a mutation in a functional region can also have an
impact on overall protein stability.
4. Conclusions
In this work we have analysed the effects of missense mutations in
ETF which correspond to different clinical presentations in MADD
patients, combining in silico studies with experimental biophysical and
biochemical data. Overall, this study showed that ETFmutationsmap to
structural hotspots with respect to subunit interaction, cofactor binding
and interaction with partner proteins, and this provides a framework
that allows to predict more accurately the probability for a given
mutation to affect protein function. Variations leading to severe
phenotypes do not map to a particular structural region and a direct
correlation with the clinical display can not be generalised, a general
problem that has hampered the prediction of mutation effects for many
disease-relevant proteins. However, it appears that amino acid changes
that lead to drastic alterations of the chemical properties of residues
involved in catalytic regions and subunit interactions have a higher
probability to result in severe effects. Among these is ETFβ-p.Cys42Arg
which results in a protein that is unable to fold: such mutations will be
clearly associatedwith severe clinical phenotypes. Othermutationswill
affect folding, cofactor binding, and assembly to different degrees, and
most of them will be associated with mild phenotypes. The degree of
impairment in respect to the clinical display is rather difﬁcult to predict,
as different effects can be observed: cofactor binding, interaction with
partner proteins and conformational stability. A key aspect arising from
our study is the fact that conformational instability of dynamic
substructures may be transferred to other parts of the protein, affecting
the protein as a whole [26–28] . That is for example the case of ETFβ-p.
Asp128Asn variant, in which the modiﬁcation of a residue which has
long range interactions with the cofactor, increases cofactor lability,
decreases protein stability and interaction with the partner dehydro-
genase. Likewise, the ETFβ–p.Arg191Cys variation directly affecting the
recognition loop also decreases protein stability, as removal of the
positively charged Arg will disrupt electrostatic interactions with the
acidic residues within helix α1 (Fig. 2). This effect then propagates to
the whole structure, affecting its conformational stability. The observa-
tionsmade for ETF represent a scenario, which is also relevant for many
other proteins, as it underpins the necessity to perform and carefully
evaluate experimental expression of clinical protein variants in order to
collect more data that will contribute to establish general principles
that can be used to more accurately predict the functional outcome of
genetic variations in metabolic disease.
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